YOLFTbeta
Invivyd Inc.

Invivyd Inc.

IVVD · NASDAQ · Healthcare / Biotechnology

0.5821USD+0.01 (+2.61%)

Price History

Full chart

Market Stats

Previous Close0.5673
Open0.5735
Day Range0.54 – 0.5885
52-Week Range0.528 – 3.07
Volume3.15M
Market Cap280.02M
P/E (TTM)0.00
Forward P/E44.64
EPS-0.31
Dividend Yield0.00%
Beta0.81
50-Day Avg0.7775
200-Day Avg1.39

About

Invivyd, Inc., together with its subsidiaries, engages in the research, development, commercialization, and sale of antibody therapies for the prevention and treatment of viral infectious diseases in the United States. The company offers Pemivibart, a half-life extended investigational monoclonal antibody for the pre-exposure prophylaxis prevention of COVID-19 in adults and adolescents through injection under the PEMGARDA brand. It also develops VYD2311, a monoclonal antibody, which is in Phase III clinical trial for the prevention and treatment of SARS-CoV-2 virus; and VBY329, a monoclonal antibody, which is in pre-clinical trial stage for the prevention and treatment of respiratory syncytial virus and measles in neonates, infants, and children. It has a collaboration agreement with Adimab, LLC for the discovery and optimization of proprietary antibodies. The company was formerly known as Adagio Therapeutics, Inc. and changed its name to Invivyd, Inc. in September 2022. Invivyd, Inc. was incorporated in 2020 and is headquartered in New Haven, Connecticut.

Company Details

  • SectorHealthcare
  • IndustryBiotechnology
  • CEOMr. Marc William Elia
  • Employees122
  • Headquarters209 Church Street, New Haven, CT, United States, 06510, USA
  • Websitehttps://www.invivyd.com

Leadership

  • Mr. Marc William EliaCEO & Chairperson of the Board · b. 1976
  • Mr. William E. Duke Jr., M.B.A.CFO and Principal Financial & Accounting Officer · b. 1972
  • Ms. Jill Andersen J.D.Chief Legal Officer & Corporate Secretary · b. 1973
  • Mr. Timothy LeeChief Commercial Officer · b. 1974
  • Dr. Robert D. Allen Ph.D.Chief Scientific Officer · b. 1970
  • Ms. Kristie Coneys Kuhl J.D.Chief Communications Officer
  • Ms. Julie Green M.B.A.Chief Human Resources Officer · b. 1976
  • Ms. Rachael Gerlach Ph.D.Senior Vice President of Regulatory Affairs
  • Ms. Katie Falzone CPASenior Vice President of Finance
  • Dr. Michael J. Mina M.D., Ph.D.Chief Medical Officer & Chief Epidemiologist · b. 1984

Financials

Income Statement

Currency: USD2020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Total Revenue-00025.38M53.43M
Growth (%)-----+110.47%
Cost of Revenue-1.00K462.00K2.03M1.62M3.75M
Gross Profit--1.00K-462.00K-2.03M23.77M49.68M
Gross Margin----93.63%92.99%
Operating Expense-226.91M247.57M210.73M200.64M105.24M
Operating Income-111.99M-226.91M-248.03M-212.76M-176.88M-55.56M
Operating Margin-----696.80%-103.99%
EBITDA-65.33M-219.41M-225.80M-205.75M-166.81M-50.38M
EBITDA Margin-----657.15%-94.30%
Net Income-111.98M-226.79M-241.32M-198.64M-169.93M-52.49M
Net Income Margin-----669.42%-98.25%
R&D106.49M182.89M179.21M158.66M137.25M38.31M
R&D as % of Total Revenue----540.71%71.70%
Interest Expense-15.00M43.08M---

Balance Sheet

Currency: USD2020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Total Assets117.38M620.09M383.17M229.18M129.51M276.88M
Total Liabilities182.63M62.07M27.20M51.71M61.98M35.34M
Total Equity-65.25M558.02M355.97M177.47M67.54M241.54M
Cash114.99M542.22M92.08M200.64M69.35M226.69M
Total Debt--3.72M2.17M1.30M2.49M
Net Debt-114.99M-542.22M-88.35M-198.48M-68.05M-224.19M

Cash Flow

Currency: USD2020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Operating Cash Flow-14.57M-184.74M-219.99M-173.16M-170.49M-58.13M
Investing Cash Flow-50.71M-50.71M-230.67M280.68M-140.00K-155.00K
Financing Cash Flow129.56M662.68M506.00K1.04M39.33M215.63M
Capital Expenditure84.00K84.00K1.71M615.00K140.00K155.00K
Free Cash Flow-14.57M-184.82M-221.69M-173.78M-170.63M-58.29M
FCF to OCF100.00%100.05%100.78%100.36%100.08%100.27%

Earnings

Report DateJun 2, 2021Sep 20, 2021Nov 15, 2021Mar 30, 2022May 13, 2022Aug 15, 2022Nov 10, 2022Mar 23, 2023May 11, 2023Aug 10, 2023Nov 9, 2023Mar 28, 2024May 9, 2024Aug 14, 2024Nov 14, 2024Mar 26, 2025May 15, 2025Aug 14, 2025Nov 6, 2025Mar 26, 2026May 14, 2026Aug 13, 2026Nov 5, 2026
EPS Estimate-0.60-0.80-0.57-1.03-0.56-0.50-0.37-0.39-0.48-0.45-0.50-0.42-0.39-0.39-0.35-0.10-0.040.01-0.09-0.09-0.08-0.15-0.11
EPS Actual-2.14-0.18-0.89-0.77-0.91-0.47-0.42-0.25-0.32-0.46-0.36-0.67-0.38-0.40-0.51-0.15-0.14-0.12-0.06-0.04-0.13-0.14-
Surprise-256.67%77.50%-56.14%25.24%-62.50%6.00%-13.51%35.90%33.33%-2.22%28.00%-59.52%2.56%-2.56%-45.71%-50.00%-250.00%-1300.00%33.33%54.51%-62.50%6.67%-
Timing-After-hoursAfter-hoursPre-marketPre-marketPre-marketAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursPre-marketAfter-hoursPre-marketPre-marketPre-marketPre-marketAfter-hoursPre-market-Pre-marketAfter-hoursAfter-hours

Key Statistics & Ratios

Market Cap280.02M
Enterprise Value120.02M
Trailing P/E0.00
Forward P/E44.64
Price / Sales4.80
Price / Book1.50
EPS-0.31
Book Value0.614
Revenue (TTM)58.37M
Gross Profit (TTM)53.83M
EBITDA-111.89M
Profit Margin-183.90%
Operating Margin-320.76%
Return on Equity-95.89%
Return on Assets-45.67%
Shares Outstanding294.76M
Shares Float207.83M
Beta0.81
Dividend Yield0.00%
Dividend Rate0.00
Payout Ratio0.00%

Analyst Ratings

Buy
Based on 3 analystsTarget 10.00
  • Strong Buy
    1
  • Buy
    1
  • Hold
    1

Ownership Breakdown

Institutions
86.88%
Insiders
7.16%
Retail / Other
5.96%

Top Institutional Holders

  • HHG PLC
    33.09M11.23%
  • Bvf Inc
    19.52M6.62%
  • Maverick Capital Ltd
    18.97M6.44%
  • Perceptive Advisors LLC
    18.49M6.27%
  • Vanguard Capital Management, LLC
    10.07M3.42%
  • M28 Capital Management LP
    9.25M3.14%
  • Driehaus Capital Management LLC
    8.44M2.86%
  • Saturn V Capital Management LLC
    8.39M2.85%
  • Soleus Capital Management, L.P.
    7.71M2.62%
  • State Street Corp
    6.94M2.35%
  • BlackRock Inc
    4.28M1.45%
  • Siren, L.L.C.
    4.00M1.36%
  • ADAR1 Capital Management LLC
    3.82M1.30%
  • StemPoint Capital LP
    3.75M1.27%
  • Adage Capital Partners Gp LLC
    3.66M1.24%
  • Citadel Advisors Llc
    3.58M1.21%
  • Balyasny Asset Management LLC
    3.52M1.19%
  • Morgan Stanley - Brokerage Accounts
    3.39M1.15%

Top Fund Holders

  • Vanguard MStar Total Stk Mkt Idx Invest
    7.79M2.64%
  • iShares Russell 2000 ETF
    5.29M1.80%